WeightLiteracy.

News & Research

What’s changing in weight health—and what it means for you.

Selected updates, with context from WeightLiteracy. Dates show when each source was published; evidence labels distinguish early findings from established care.

Our editorial standards
Metabolic research

Brown-fat research points to questions, not a new weight-loss treatment

National Institutes of Health · Human observations + animal research

NIH reports that researchers linked blood-pressure medicines called ARBs with greater brown-fat activity in medical records from more than 100,000 people who underwent cancer imaging. Follow-up experiments found that losartan increased brown-fat activity in cells and mice. The treated mice maintained a steady body weight.

Why it mattersBrown fat uses energy to produce heat. Studying it may help explain metabolism, but a change in its activity does not by itself establish a useful weight-loss treatment.

Keep in mindThe human findings are observational, and the treatment experiments were not a human weight-loss trial. This is not a reason to start or change blood-pressure medicine.

Read original source Our guide: Insulin Resistance, Explained Without the Jargon
Access & affordability

Treatment costs deserve a place in the care conversation

American Diabetes Association · Survey findings

An American Diabetes Association survey highlights the financial pressure of diabetes and obesity care. Nearly one in four surveyed households reported spending at least $200 a month on obesity medicines. The online survey gathered responses in June and July 2026 from ADA advocates and market-research panel participants.

Why it mattersBefore choosing a service, ask about the combined cost of medicine, appointments, tests, and follow-up, and what happens if coverage changes. A low advertised starting price may not describe the full plan.

Keep in mindThese are self-reported experiences from participating households, not a price quote or a guarantee of what any individual will pay. The announcement does not establish that its percentages represent every US household.

Read original source Our guide: How to Choose a Telehealth Weight-Loss Service
Medication safety

FDA review changes guidance on GLP-1 mood warnings

US Food and Drug Administration · FDA safety communication

In January 2026, FDA requested removal of the suicidal-thoughts-and-behavior warning from Saxenda, Wegovy, and Zepbound labeling after its review found no increased risk associated with GLP-1 medicines. Its analysis included 91 placebo-controlled trials with 107,910 participants, alongside other evidence.

Why it mattersOlder articles may still describe the previous warning. Check the current information for your exact medicine and discuss concerns with your prescriber.

Keep in mindThis finding addresses a specific safety question; it does not mean these medicines have no risks. New or worsening depression or unusual mood changes still warrant prompt professional attention.

Read original source Our guide: GLP-1 Side Effects: What’s Common and When to Get Help

Looking for the bigger picture?

Our educational guides explain the basics behind the headlines, from appetite and metabolism to treatment decisions.

Explore our articles